Federal Register / Vol. 72, No. 166 / Tuesday, August 28, 2007 / Notices 49283 

Dated: August 21, 2007. 

John J. McGowan, 

Deputy Director for Science Management, 

NIAID, National Institutes of Health. 

[FR Doc. E7–17012 Filed 8–27–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Establishment 

Pursuant to the Federal Advisory 

Committee Act, as amended (5 U.S.C. 

Appendix 2), the Director, National 

Institutes of Health (NIH), announces 

the establishment of the Scientific 

Management Review Board (SMRB). 

The NIH Reform Act of 2006 (Pub. L. 

109–482) provides organizational 

authorities to HHS and NIH officials to: 

(1) Establish or abolish national research 

institutes; (2) reorganize the offices 

within the Office of the Director, NIH 

including adding, removing, or 

transferring the functions of such offices 

or establishing or terminating such 

offices; and (3) reorganize, divisions, 

centers, or other administrative units 

within an NIH national research 

institute or national center including 

adding, removing, or transferring the 

functions of such units, or establishing 

or terminating such units. The purpose 

of the Scientific Management Review 

Board (also referred to as SMRB or 

Board) is to advise appropriate HHS and 

NIH officials on the use of these 

organizational authorities and identify 

the reasons underlying the 

recommendations. 

Duration of this committee is tow 

years from the date of Charter is filed. 

Dated: August 20, 2007. 

Elias A. Zerhouni, 

Director, National Institutes of Health. 

[FR Doc. 07–4221 Filed 8–27–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Development of Antigenic Chimeric St. 

Louis Encephalitis Virus/Dengue Virus 

Type Four Recombinant Viruses (SLEV/ 

DEN4) as Vaccine Candidates for the 

Prevention of Disease Caused by SLEV 

Description of Invention: St. Louis 

Encephalitis Virus (SLEV) is a 

mosquito-borne flavivirus that is 

endemic in the Americas and causes 

sporadic outbreaks of disease in 

humans. SLEV is a member of the 

Japanese encephalitis virus serocomplex 

and is closely related to West Nile Virus 

(WNV). St. Louis encephalitis is found 

throughout North, Central, and South 

America, and the Caribbean, but is a 

major public health problem mainly in 

the United States. Prior to the outbreak 

of West Nile virus in 1999, St. Louis 

encephalitis was the most common 

human disease caused by mosquitoes in 

the United States. Since 1964, there 

have been about 4,440 confirmed cases 

of St. Louis encephalitis, with an 

average of 130 cases per year. Up to 

3,000 cases have been reported during 

epidemics in some years. Many more 

infections occur without symptoms and 

go undiagnosed. At present, a vaccine or 

FDA approved antiviral therapy is not 

available. 

The inventors have previously 

developed a WNV/Dengue4Delta30 

antigenic chimeric virus as a live 

attenuated virus vaccine candidate that 

contains the WNV premembrane and 

envelope (prM and E) proteins on a 

dengue virus type 4 (DEN4) genetic 

background with a thirty nucleotide 

deletion (Delta30) in the DEN4 3’-UTR. 

Using a similar strategy, the inventors 

have generated an antigenic chimeric 

virus, SLE/DEN4Delta30. Preclinical 

testing results indicate that 

chimerization of SLE with DEN4Delta30 

decreased neuroinvasiveness in mice, 

did not affect neurovirulence in mice, 

and appeared to overattenuate the virus 

for non-human primates. Modifications 

of the SLE/DEN4Delta30 vaccine 

candidate are underway to improve its 

immunogenicity. 

This application claims live 

attenuated chimeric SLE/DEN4Delta30 

vaccine compositions and bivalent 

WNV/SLE/DEN4Delta30 vaccine 

compositions. Also claimed are methods 

of treating or preventing SLEV infection 

in a mammalian host, methods of 

producing a subunit vaccine 

composition, isolated polynucleotides 

comprising a nucleotide sequence 

encoding a SLEV immunogen, methods 

for detecting SLEV infection in a 

biological sample and infectious 

chimeric SLEV. 

Application: Immunization against 

SLEV or SLEV and WNV. 

Development Status: Live attenuated 

vaccine candidates are currently being 

developed and preclinical studies in 

mice and monkeys are in progress. 

Suitable vaccine candidates will then be 

evaluated in clinical studies. 

Inventors: Stephen S. Whitehead, 

Joseph Blaney, Alexander Pletnev, Brian 

R. Murphy (NIAID). 

Patent Status: U.S. Provisional 

Application No. 60/934,730 filed 14 Jun 

2007 (HHS Reference No. E–240–2007/ 

0–US–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Collaborative Research Opportunity: 

The NIAID Laboratory of Infectious 

Diseases is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize live attenuated virus 

vaccine candidates for St. Louis 

encephalitis virus. Please contact Dr. 

Whitehead at 301–496–7692 for more 

information. 

Monoclonal Antibodies Against Dengue 

and Other Viruses With Deletion in Fc 

Region 

Description of Invention: The four 

dengue virus (DENV) serotypes (DENV–

1 to DENV–4) are the most important 

arthropod-borne flaviviruses in terms of 

morbidity and geographic distribution. 

Up to 100 million DENV infections 

occur every year, mostly in tropical and 

subtropical areas where vector 

mosquitoes are abundant. Infection with 

any of the DENV serotypes may be 

asymptomatic or may lead to classic 

dengue fever or more severe dengue 

hemorrhagic fever (DHF) and dengue 

shock syndrome (DSS), which are 

increasingly common in the dengue 

endemic areas. Immunity to the same 

virus serotype (homotypic immunity) is 

life-long, whereas immunity to different 

serotypes (heterotypic immunity) lasts 


pwalker on PROD1PC71 with NOTICES